References
- BeckerSA historic and scientific review of breast cancer: The next global healthcare challengeInt J Gynaecol Obstet2015131Suppl 1S36S3926433503
- SlamonDJClarkGMWongSGLevinWJUllrichAMcGuireWLHuman breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogeneScience198723547851771823798106
- SadeghiSOlevskyOHurvitzSAProfiling and targeting HER2-positive breast cancer using trastuzumab emtansinePharmgenomics Pers Med2014732933825378946
- MartyMCognettiFMaraninchiDRandomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study groupJ Clin Oncol200523194265427415911866
- RodallecAFanciullinoRLacarelleBCiccoliniJSeek and destroy: improving PK/PD profiles of anticancer agents with nanoparticlesExpert Rev Clin Pharmacol201811659961029768060
- RodallecABrunelJMGiacomettiSDocetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancerInt J Nanomedicine2018133451346529950829
- KijanskaMKelmJIn vitro 3D spheroids and microtissues: ATP-based cell viability and toxicity assaysSittampalamGSAssay Guidance ManualBethesda, MDEli Lilly & Company and the National Center for Advancing Translational Sciences2004 Available from: http://www.ncbi.nlm.nih.gov/books/NBK343426/Accessed May 25, 2018
- RodallecABenzekrySLacarelleBCiccoliniJFanciullinoRPharmacokinetics variability: Why nanoparticles are not just magic-bullets in oncologyCrit Rev Oncol Hematol201812911230097227
- RothASingerTThe application of 3D cell models to support drug safety assessment: opportunities & challenges.Adv Drug Deliv Rev2014697017918925451857
- YangTChoiMKCuiFDPreparation and evaluation of paclitaxel-loaded PEGylated immunoliposomeJ Control Release2007120316917717586082
- ChoiWI“Targeted antitumor efficacy and imaging via multifunctional nanocarrier conjugated with anti-HER2 trastuzumab,” Nanomedicine: NanotechnologyBiol Med2015112359368
- SoemaPCWillemsGJJiskootWAmorijJPKerstenGFPredicting the influence of liposomal lipid composition on liposome size, zeta potential and liposome-induced dendritic cell maturation using a design of experiments approachEur J Pharm Biopharm20159442743526144666
- GargMBAcklandSPSimple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urineJ Chromatogr B Biomed Sci Appl2000748238338811087080
- BradfordMMA rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnal Biochem197672248254942051
- CarterPJLazarGANext generation antibody drugs: pursuit of the ‘high-hanging fruit’Nat Rev Drug Discov201817319722329192287
- MaedaHThe enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targetingAdv Enzyme Regul200141118920711384745
- BregoliL“Nanomedicine applied to translational oncology: A future perspective on cancer treatment,” Nanomedicine: NanotechnologyBiol Med201612181103
- GoduguCPatelARDesaiUAndeyTSamsASinghMAlgiMatrix™ Based 3D Cell Culture System as an In-Vitro Tumor Model for Anticancer StudiesPLoS One201381e5370823349734
- GuoLZhouYWangSWuYEpigenetic changes of mesenchymal stem cells in three-dimensional (3D) spheroidsJ Cell Mol Med201418102009201925090911
- ShaHZouZXinKTumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapyJ Control Release201520018820025553823
- Lal-NagMExploring drug dosing regimens in vitro using real-time 3d spheroid tumor growth assaysSLAS Discov20172253754628298153
- HareJILammersTAshfordMBPuriSStormGBarrySTChallenges and strategies in anti-cancer nanomedicine development: An industry perspectiveAdv Drug Deliv Rev2017108253827137110
- FanciullinoRMollardSCorreardFBiodistribution, tumor uptake and efficacy of 5-FU-loaded liposomes: why size mattersPharm Res201431102677268424752479
- KirpotinDBDrummondDCShaoYAntibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal modelsCancer Res200666136732674016818648
- HollidayDLSpeirsVChoosing the right cell line for breast cancer researchBreast Cancer Res201113421521884641
- EricksonHKLewis PhillipsGDLeipoldDDThe effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugatesMol Cancer Ther20121151133114222408268
- YangTChoiMKCuiFDAntitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cellsPharm Res200724122402241117828616
- EloyJOPetrilliRChescaDLSaggioroFPLeeRJMarchettiJMAnti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapyEur J Pharm Biopharm201711515916728257810